IN2014DN06118A - - Google Patents
Info
- Publication number
- IN2014DN06118A IN2014DN06118A IN6118DEN2014A IN2014DN06118A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A IN 6118DEN2014 A IN6118DEN2014 A IN 6118DEN2014A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A
- Authority
- IN
- India
- Prior art keywords
- oncogenic viral
- immune response
- polypeptide
- polypeptides
- subject
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 231100000590 oncogenic Toxicity 0.000 abstract 5
- 230000002246 oncogenic effect Effects 0.000 abstract 5
- 230000003612 virological effect Effects 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590089P | 2012-01-24 | 2012-01-24 | |
| PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06118A true IN2014DN06118A (enExample) | 2015-08-14 |
Family
ID=48873849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6118DEN2014 IN2014DN06118A (enExample) | 2012-01-24 | 2013-01-23 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9492526B2 (enExample) |
| EP (2) | EP2806889B1 (enExample) |
| JP (2) | JP6219849B2 (enExample) |
| KR (1) | KR102195196B1 (enExample) |
| CN (2) | CN104159607A (enExample) |
| DK (1) | DK2806889T3 (enExample) |
| ES (1) | ES2646590T3 (enExample) |
| HK (1) | HK1203833A1 (enExample) |
| IN (1) | IN2014DN06118A (enExample) |
| WO (1) | WO2013112549A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| GB201605210D0 (en) | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| JP2019517522A (ja) * | 2016-06-03 | 2019-06-24 | エトゥビクス コーポレーション | ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法 |
| CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
| CN109891405B (zh) * | 2016-11-11 | 2023-09-26 | 谷歌有限责任公司 | 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质 |
| SG11202008539YA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
| IL296509A (en) | 2020-03-16 | 2022-11-01 | Univ North Carolina Chapel Hill | Preparations and methods for selective detection of tumor-derived viral DNA |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| AU2021281910C1 (en) * | 2020-05-25 | 2024-09-19 | Genematrix Inc. | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein |
| KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
| CN116425839A (zh) * | 2023-04-03 | 2023-07-14 | 深圳锦时生物科技有限公司 | 人乳头瘤病毒多肽及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| WO1999061608A2 (en) * | 1998-05-26 | 1999-12-02 | Institute Of Molecular And Cell Biology | Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation |
| CA2499837C (en) * | 2002-10-03 | 2013-12-03 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
| KR101514473B1 (ko) * | 2007-05-15 | 2015-04-22 | 트랜스진 에스.에이. | 다중 유전자 발현용 벡터 |
| WO2010129339A2 (en) * | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en not_active Ceased
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/en active Active
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active Active
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 HK HK15104469.7A patent/HK1203833A1/xx unknown
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/en active Active
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2806889A1 (en) | 2014-12-03 |
| EP2806889B1 (en) | 2017-08-16 |
| CN104159607A (zh) | 2014-11-19 |
| JP2015506179A (ja) | 2015-03-02 |
| CN110042110A (zh) | 2019-07-23 |
| EP2806889A4 (en) | 2016-04-20 |
| US9969779B2 (en) | 2018-05-15 |
| US9492526B2 (en) | 2016-11-15 |
| JP2018038405A (ja) | 2018-03-15 |
| KR102195196B1 (ko) | 2020-12-28 |
| US20180237477A1 (en) | 2018-08-23 |
| EP3269387B1 (en) | 2019-07-17 |
| KR20140131929A (ko) | 2014-11-14 |
| HK1203833A1 (en) | 2015-11-06 |
| US20150023996A1 (en) | 2015-01-22 |
| DK2806889T3 (da) | 2017-11-20 |
| JP6219849B2 (ja) | 2017-10-25 |
| ES2646590T3 (es) | 2017-12-14 |
| WO2013112549A1 (en) | 2013-08-01 |
| JP6655051B2 (ja) | 2020-02-26 |
| US20160376324A1 (en) | 2016-12-29 |
| EP3269387A1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600709A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| IN2014KN02929A (enExample) | ||
| IN2014DN10288A (enExample) | ||
| IN2012DN01920A (enExample) | ||
| MX363307B (es) | Plataformas para suministro de antigenos. | |
| MY172578A (en) | Oral dosing of glp-1 compounds | |
| MX2022016002A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| NZ600974A (en) | Binding members for human cytomegalovirus | |
| IN2014KN03063A (enExample) | ||
| NZ627078A (en) | Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy | |
| MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| UA110024C2 (uk) | Вакцинний вектор і спосіб посилення імунної відповіді | |
| IL220092A (en) | 44cd monoclonal antibody for use in the treatment of squamous cell carcinoma of the head and neck | |
| MX2025008006A (es) | Vacunas novedosas del vph16, composiciones y metodos de uso de las mismas | |
| NZ603863A (en) | Concentration and lyophilization of influenza vaccine antigens | |
| WO2014004385A3 (en) | Anti-cancer vaccines | |
| PH12014500219A1 (en) | Polyacrylate-based active compound-comprising particles | |
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
| SI2859092T1 (sl) | Terapevtsko cepivo za zdravljenje diabetesa tipa 1 pri otrocih, uporaba naprave za sortiranje celic in postopek multipliciranja TREG celic za pridobivanje terapevtskega cepiva za zdravljenje diabetesa tipa 1 | |
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| CL2012003219A1 (es) | Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal. |